FTI-277

• Description:

  FTI-277 is an inhibitor of farnesyl transferase (FTase) ; a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 can inhibit hepatitis delta virus (HDV) infection.

• UNSPSC:

  12352005

• Hazard Statement:

  H315-H319-H335

• Target:

  Apoptosis; Farnesyl Transferase; Ras

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/FTI-277.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CSCC[C@@H](C(OC)=O)NC(C1=CC=C(NC[C@@H](N)CS)C=C1C2=CC=CC=C2)=O

• Molecular Formula:

  C22H29N3O3S2

• Molecular Weight:

  447.61

• Precautions:

  P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Cohen-Jonathan E, et al. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat Res. 1999 Oct;152 (4) :404-11.|[2]Nakazawa H, et al. Role of protein farnesylation in burn-induced metabolic derangements and insulin resistance in mouse skeletal muscle. PLoS One. 2015 Jan 16;10 (1) :e0116633.|[3]Virtanen SS, et al. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells. Cell Biol Int. 2010 Aug;34 (8) :815-26.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  Fish Shellfish Immunol. 2019 Apr 3;89:281-289.|Oncotarget. 2017 Nov 22;8 (65) :109135-109150. |Adv Sci (Weinh) . 2024 Jun 18:e2307751.|FEBS Open Bio. 2025 Aug 8.|J Cell Mol Med. 2024 Dec;28 (24) :e70273.|Mol Cell Proteomics. 2023 Aug;22 (8) :100593.

• CAS Number:

  170006-73-2